Regimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial design. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - Sep 23, 2026 - "The study was registered with PROSPERO: CRD420261288549. On MG-ADL, zilucoplan led with the highest Emax (4.8 points; 95% CrI: 4.2-5.4) and largest net benefit (2.5; 2.0-3.1)...Efgartigimod achieved the fastest onset on both scales (≤ 1.6 weeks)...For rozanolixizumab on MG-ADL, snapshot week 26 endpoints were underpowered (65%); integrated endpoints recovered power to 94-95%...Across the multi dimensional treatment-selection framework integrating efficacy, safety, tolerability, and convenience, batoclimab emerged as the highest-ranked agent in all eight clinical priority profiles. These findings provide a pharmacodynamic evidence base for mechanism-guided treatment individualisation and endpoint optimisation in generalised myasthenia gravis."
Journal • Retrospective data • CNS Disorders • Immunology • Myasthenia Gravis
|
|
Abhishek Anil; Anand Srinivasan; Apoorva Wasnik; Biswa Mohan Padhy; Debasish Hota; Sayantan Shankar Roy
|